Herriot Tabuteau is CEO at Axsome Therapeutics, Inc. (AXSM). They have made 1 open-market trade across 1 company since 2025, most recently 2026-08-06.
CIK 0001219927
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AXSM | 7,229 | $1.1M |
Shares reported on the most recent Form 4, priced at the 2026-08-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AXSM | SELL · 10b5-1 | 2026-08-05 | 2026-08-07 | $212.19 | $10.5M | +0.7% | -4.3% | — |
| AXSM | SELL · 10b5-1 | 2026-07-01 | 2026-07-01 | $240.25 | $11.9M | -2.0% | -9.1% | -22.4% |
| AXSM | SELL · 10b5-1 | 2026-06-09 | 2026-06-09 | $241.01 | $12.0M | -1.3% | -0.9% | -17.3% |
| AXSM | SELL · 10b5-1 | 2026-02-02 | 2026-02-02 | $185.60 | $6.0M | -2.8% | -12.8% | +18.8% |
| AXSM | SELL | 2026-01-05 | 2026-01-07 | $171.30 | $23.9M | +9.2% | +8.0% | -0.1% |
| AXSM | SELL · 10b5-1 | 2025-12-02 | 2025-12-04 | $145.66 | $23.3M | -0.8% | +15.9% | +10.9% |
| AXSM | SELL · 10b5-1 | 2025-11-03 | 2025-11-05 | $133.07 | $43.6M | +7.3% | +10.0% | +38.1% |
| AXSM | SELL · 10b5-1 | 2025-10-06 | 2025-10-08 | $119.38 | $10.8M | +10.9% | +16.4% | +44.8% |
| AXSM | SELL · 10b5-1 | 2025-09-12 | 2025-09-16 | $117.08 | $14.7M | +2.0% | +9.2% | +27.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.